These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 17559990

  • 1. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults.
    Atmar RL, Keitel WA, Cate TR, Munoz FM, Ruben F, Couch RB.
    Vaccine; 2007 Jul 20; 25(29):5367-73. PubMed ID: 17559990
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
    Frenck RW, Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, Hay CM, Dekker CL, Walter EB, Cate TR, Edwards KM, Hill H, Wolff M, Leduc T, Tornieporth N.
    Vaccine; 2011 Aug 05; 29(34):5666-74. PubMed ID: 21699951
    [Abstract] [Full Text] [Related]

  • 4. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™).
    Fernando GJP, Hickling J, Jayashi Flores CM, Griffin P, Anderson CD, Skinner SR, Davies C, Witham K, Pryor M, Bodle J, Rockman S, Frazer IH, Forster AH.
    Vaccine; 2018 Jun 18; 36(26):3779-3788. PubMed ID: 29779922
    [Abstract] [Full Text] [Related]

  • 5. Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine.
    Muszkat M, Greenbaum E, Ben-Yehuda A, Oster M, Yeu'l E, Heimann S, Levy R, Friedman G, Zakay-Rones Z.
    Vaccine; 2003 Mar 07; 21(11-12):1180-6. PubMed ID: 12559796
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
    Frey SE, Bernstein DI, Brady RC, Keitel WA, El Sahly H, Rouphael NG, Mulligan MJ, Atmar RL, Edupuganti S, Patel SM, Dickey M, Graham I, Anderson EL, Noah DL, Hill H, Wolff M, Belshe RB.
    Vaccine; 2015 Jan 01; 33(1):163-73. PubMed ID: 25444805
    [Abstract] [Full Text] [Related]

  • 7. Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.
    Garg S, Thongcharoen P, Praphasiri P, Chitwarakorn A, Sathirapanya P, Fernandez S, Rungrojcharoenkit K, Chonwattana W, Mock PA, Sukwicha W, Katz JM, Widdowson MA, Curlin ME, Gibbons RV, Holtz TH, Dawood FS, Olsen SJ.
    Clin Infect Dis; 2016 Feb 01; 62(3):383-391. PubMed ID: 26486702
    [Abstract] [Full Text] [Related]

  • 8. Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM): A randomized, double-blind, controlled, ascending dose study in healthy adults and elderly.
    van der Plas JL, Haijema BJ, Leenhouts K, Paul Zoeteweij J, Burggraaf J, Kamerling IMC.
    Vaccine; 2024 Sep 17; 42(22):125836. PubMed ID: 38772837
    [Abstract] [Full Text] [Related]

  • 9. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
    Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, Gorfinkel I, Shu D, White L, Lasko B, Dzongowski P, Papp K, Alexander M, Boivin G, Fries L.
    Vaccine; 2011 Feb 24; 29(10):1921-8. PubMed ID: 21219987
    [Abstract] [Full Text] [Related]

  • 10. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH.
    Vaccine; 2013 May 01; 31(19):2358-65. PubMed ID: 23499604
    [Abstract] [Full Text] [Related]

  • 11. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.
    Vaccine; 2012 Jul 06; 30(32):4884-91. PubMed ID: 22537989
    [Abstract] [Full Text] [Related]

  • 12. Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults.
    Halperin SA, Smith B, Clarke K, Treanor J, Mabrouk T, Germain M.
    Hum Vaccin; 2005 Jul 06; 1(1):37-42. PubMed ID: 17038827
    [Abstract] [Full Text] [Related]

  • 13. A double-blind trial of a new inactivated, trivalent, intra-nasal anti-influenza vaccine in general practice: relationship between immunogenicity and respiratory morbidity over the winter of 1997-98.
    Kiderman A, Furst A, Stewart B, Greenbaum E, Morag A, Zakay-Rones Z.
    J Clin Virol; 2001 Feb 06; 20(3):155-61. PubMed ID: 11166665
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
    Carter C, Houser KV, Yamshchikov GV, Bellamy AR, May J, Enama ME, Sarwar U, Larkin B, Bailer RT, Koup R, Chen GL, Patel SM, Winokur P, Belshe R, Dekker CL, Graham BS, Ledgerwood JE, VRC 703 study team.
    PLoS One; 2019 Feb 06; 14(9):e0222178. PubMed ID: 31532789
    [Abstract] [Full Text] [Related]

  • 15. Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults.
    Ainai A, Tamura S, Suzuki T, van Riet E, Ito R, Odagiri T, Tashiro M, Kurata T, Hasegawa H.
    Hum Vaccin Immunother; 2013 Sep 06; 9(9):1962-70. PubMed ID: 23896606
    [Abstract] [Full Text] [Related]

  • 16. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects.
    Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, Fries L.
    Vaccine; 2006 Jan 16; 24(3):254-62. PubMed ID: 16129526
    [Abstract] [Full Text] [Related]

  • 17. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 16; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults.
    Chi RC, Rock MT, Neuzil KM.
    Clin Infect Dis; 2010 May 15; 50(10):1331-8. PubMed ID: 20377407
    [Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
    Gorse GJ, Falsey AR, Johnson CM, Morrison D, Fried DL, Ervin JE, Greenberg DP, Ozol-Godfrey A, Landolfi V, Tsang PH.
    Vaccine; 2013 Dec 05; 31(50):6034-40. PubMed ID: 24055306
    [Abstract] [Full Text] [Related]

  • 20. Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults.
    Langley JM, Halperin SA, McNeil S, Smith B, Jones T, Burt D, Mallett CP, Lowell GH, Fries L.
    Vaccine; 2006 Mar 06; 24(10):1601-8. PubMed ID: 16303215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.